Fig. 8 | Experimental & Molecular Medicine

Fig. 8

From: The role of FGF-2 in smoke-induced emphysema and the therapeutic potential of recombinant FGF-2 in patients with COPD

Fig. 8

Change in pulmonary function tests (PFTs) [a change in forced expiratory flow in 1 s (Δ FEV1) and b change in forced vital capacity (Δ FVC)] during and after fibroblast growth factor (FGF)-2 treatment. PFTs, including FEV1 and FVC, tended to improve during the recombinant (r) FGF-2 treatment period but not significantly between the rFGF-2 group and the control group (p > 0.05)

Back to article page